Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.

Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis remains unexplored in Japan. This study aimed to investigate the long-term survival and prognostic factors of radioiodine therapy (RIT) in a University Hospital setting. This retrospective study included 62 patients with lung metastases from DTC who received RIT between March 2005 and December 2016.

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men.

Background: Treatment strategies have changed dramatically in recent years with the development of a variety of agents for metastatic hormone-naïve prostate cancer (mHNPC). There is a need to identify prognostic factors for the appropriate choice of treatment for patients with mHNPC, and we retrospectively examined these factors.

Methods: Patients with mHNPC treated at our institution from 2000 to 2019 were included in this study.

I-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (I-OI5V) imaging visualized augmented sigma-1 receptor expression according to the severity of myocardial ischemia.

Background: We aimed to explore how the severity of myocardial ischemia affects myocardial sigma-1 receptor (Sig-1R) expression using I-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (I-OI5V) imaging.

Methods And Results: The left coronary artery was occluded for 30, 20, and 10 minute, to vary the severity of myocardial ischemia, followed by reperfusion. Dual-tracer autoradiography of the left ventricular short-axis slices was performed 3 and 7 days after reperfusion.

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.

Objective: In this phase II study, we aimed to investigate the efficacy and safety of single-dose [I]meta-iodobenzylguanidine (I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL).

Patients And Methods: This study was designed as an open-label, single-arm, multi-center, phase II clinical trial. The enrolled patients were administered 7.

Feasibility of I-RGD uptake as a marker of angiogenesis after myocardial infarction.

Objective: Angiogenesis is an important process facilitating the healing process after myocardial infarction. I-RGD imaging may be a promising candidate to image angiogenesis but may also detect inflammation.

Methods: Left coronary artery was occluded for 30 min, followed by reperfusion in a rat model (n = 31).

Prognostic factors for refractory pheochromocytoma and paraganglioma after I-metaiodobenzylguanidine therapy.

Objective: Given the rarity of refractory pheochromocytoma and paraganglioma (PPGL), outcomes and prognostic factors after I-metaiodobenzylguanidine (I-mIBG) treatment still remain unclear. Therefore, this study evaluated whether baseline characteristics at initial I-mIBG therapy and imaging response to repeated I-mIBG therapy could be prognostic factors for refractory PPGL.

Methods: All patients [n = 59 (male/female = 35/24), median age; 49.

Visualization of Dynamic Expression of Myocardial Sigma-1 Receptor After Myocardial Ischemia and Reperfusion Using Radioiodine-Labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5V) Imaging.

Background: This study chronologically evaluated the expression of the intensity and distribution of the sigma-1 receptor (σ1R) demonstrated by radiolabeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5V) in a rat model of myocardial ischemia and reperfusion.

Methods and results: The left coronary artery was occluded for 30 min, followed by reperfusion. Dual-tracer autoradiography with I-OI5V and Tc-MIBI was performed to assess the spatiotemporal changes in I-OI5V uptake (n=5-6).

Diagnostic Use of Post-therapy I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma.

I-meta-iodobenzylguanidine (I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy I-mIBG scintigraphy may detect more lesions compared with diagnostic I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic I-mIBG scintigraphy.

High-dose I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience.

Objective: Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose I-meta-iodo-benzyl-guanidine (I-mIBG) in relapsed neuroblastoma or ganglioneuroblastoma patients with complete response (CR) to induction therapy as demonstrated by diagnostic I-mIBG scintigraphy.

High-dose I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan.

Objective: The aim of the study was to investigate the outcomes and prognostic factors of high-dose I-metaiodobenzylguanidine (I-MIBG) therapy in patients with refractory or relapsed neuroblastoma (NBL) in Japan.

Methods: We retrospectively analyzed 20 patients with refractory or relapsed high-risk NBL who underwent I-MIBG therapy with an administration dose ranging from 444 to 666 MBq/kg at Kanazawa University Hospital, Japan, between September 2008 and September 2013. We focused on measurements regarding their initial responses, prognostic factors, survivals, and toxicities following I-MIBG therapy using our hospital data and questionnaires from the hospitals that these patients were initially referred from.

Utility of I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma.

Objectives: Single-photon emission computed tomography (SPECT) using metaiodobenzylguanidine (MIBG) is an important diagnostic tool for the treatment of refractory pheochromocytoma and paraganglioma (PPGL). Owing to the difficulty of SPECT quantification, the tumour-to-background ratio (TBR) is used to assess disease activity. However, the utility of TBR is limited owing to the background setting.

Prognostic Value of Early Evaluation of Left Ventricular Dyssynchrony After Myocardial Infarction.

Purpose: Dispersion in the contraction of the normally coordinate ventricular system, referred to as left ventricular (LV) dyssynchrony, is constantly observed at different grades of severity after myocardial infarction (MI). We aimed to investigate the prognostic value of early dyssynchrony in adverse cardiac events after MI in a rat model using the quantified gated single photon emission tomography (SPECT; QGS) software.

Procedures: After thoracotomy, the left coronary arteries of 16 rats were occluded and reperfused.